{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "KALV",
  "name": "KalVista Pharmaceuticals, Inc.",
  "url": "https://frontierpicks.com/dossiers/KALV/",
  "json_url": "https://frontierpicks.com/dossiers/KALV.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Resolved cash takeout, not a live security: Chiesi's $27.00/share acquisition closed 2026-06-11, KALV delisted the same morning, Form 15-12G filed 2026-06-22, and Rule 12g-4 registration termination lands ~2026-09-20. The 2026-06-10 close of $27.00 — 0.0% from the high, RSI 77 — is an artifact of a terminated series. The narrative is dead.",
  "invalidation_trigger": "A daily close below $27.00 can no longer print: KALV ceased trading on Nasdaq before the open on 2026-06-11 at the $27.00 cash consideration and filed Form 15-12G on 2026-06-22, with Rule 12g-4 termination effective ~2026-09-20. Only a rescinded merger plus a US relisting would reopen the level.",
  "catalyst_date": "2026-09-20",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "m-and-a-special-situations",
    "rare-disease-gene-therapy",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "2026-04-29: Chiesi Group definitive agreement to acquire KALV at $27.00/share cash, ~$1.9B, 36% premium to 30d VWAP.",
    "2026-04-29: Chiesi Group definitive agreement to acquire KALV at $27.00/share cash, ~$1.9B, 36% premium to 30d VWAP. Tender via Skyline Merger Sub commenced 2026-05-13.",
    "Chiesi definitive agreement to acquire KALV at $27.00/share cash, ~$1.9B, 36% premium to 30d VWAP; tender via Skyline Merger Sub commenced 2026-05-13.",
    "Delisted from Nasdaq before the open on 2026-06-11. Any KALV quote dated after 2026-06-10 is a stale feed or a grey-market artifact.",
    "Form 15-12G filed 2026-06-22: Exchange Act reporting is suspended, so no further 10-Q, 10-K or 8-K will appear for this issuer.",
    "Chiesi Farmaceutici S.p.A. is privately held — there is no listed acquirer through which to hold the EKTERLY franchise.",
    "The series ends at the 2026-06-10 close of $27.00, equal to the 52-week high; RSI, moving-average and momentum readings on it are artifacts.",
    "Third-party Schedule 13G/A filings still post to the KALV record (2026-08-11, 2026-08-14). They are former-holder housekeeping, not evidence of trading."
  ],
  "body_markdown": "## Current Thesis\nThe leg an investor would have been buying — a capped spread into a signed all-cash takeout — was paid out on **2026-06-11**, when Chiesi Farmaceutici S.p.A. completed its $27.00/share acquisition of KalVista (~$1.9B implied at closing) and the common stock ceased trading on the Nasdaq Global Market before the open. Since the last coverage on 2026-08-15 nothing has reopened it. The only forward-dated item on the file is administrative: **Form 15-12G was filed 2026-06-22**, and under Exchange Act Rule 12g-4 registration termination becomes effective 90 days later, i.e. **on or about 2026-09-20** — now inside the 30-day window. The last confirmed entries on the issuer record remain third-party Schedule 13G/A amendments dated **2026-08-11 and 2026-08-14** (SilverArc, Venrock, Tang Capital), which are former-holder housekeeping against a share that no longer trades. A public fetch of the EDGAR company index and the submissions API on 2026-08-23 returned HTTP 403, so no filing after 2026-08-14 has been verified either way here. The narrative is **dead**, dated by the 2026-06-11 delisting and the 2026-06-22 Form 15-12G. The file stays open for one reason — a price series frozen at $27.00 keeps generating a breakout signature with no venue behind it.\n\n## Bull Case\nThis section is retrospective; the payoff already occurred and no residual claim above $27.00 has emerged.\n- the second-step merger converted untendered stock at the same **$27.00** cash. Regulatory gates cleared ahead of schedule — US HSR waiting period expired 2026-05-28, German FCO clearance 2026-05-27, Italian FDI no-objection 2026-05-29 — and the 2026-06-11 close beat the original Q3-2026 placeholder.\n- **The convertible settled at parity, not as a stub.** Holders of the 3.250% Convertible Senior Notes due 2031 received **$1,606.28 in cash per $1,000 principal**, aligned to the equity consideration.\n- **The underlying asset was commercial.** EKTERLY (sebetralstat), the first oral on-demand HAE therapy, booked roughly **$49M of 2025 net revenue** after a July 2025 US launch, with US HAE penetration near 20%, **724 prescribers and 1,702 patient start forms through 2026-02-28**. That revenue floor is why deal-break odds stayed negligible into the close.\n\n## Bear Case\n- **There is no security.** Delisted 2026-06-11; Form 15-12G filed 2026-06-22. No listed share, no options chain, no reported short interest, no scheduled earnings, no future 10-Q, 10-K or 8-K flow from this issuer.\n- **The franchise is private.** Chiesi Farmaceutici S.p.A.\n- **The payoff was capped from the start.** From the 2026-04-29 announcement — a 36% premium to the 30-day VWAP — the residual spread to $27.00 ran under 2% against reversion risk toward a standalone reference in the mid-teens (52-week low $9.83). It never carried trend velocity, whatever the momentum readings say.\n- **The live hazard is data quality.** A screen keyed to pre-delisting bars will keep surfacing KALV as a 52-week-high breakout sitting above every moving average, with zero liquidity attached.\n\n## Setup & Price Structure\nThe last completed daily bar is **2026-06-10 at $27.00**, identical to the 52-week high: 0.0% distance from the high, RSI(14) of 77.1, and a trailing three-month price change of +55.4%. Those are arithmetic on a series that stops — the 55.4% is the 2026-04-29 announcement gap plus pre-deal drift, permanently frozen, and as of 2026-08-23 the series has been static for 74 calendar days. No further bar prints, so no moving average rolls over, no base forms, no structure breaks. There is nothing to trade and nothing for a chart to resolve. Any KALV quote dated after 2026-06-10 is a stale feed or a grey-market artifact; no OTC quotation or market-maker Form 211 for the symbol has been identified.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-09-20 (est.)** — Section 12(g) registration termination takes effect, 90 days after the 2026-06-22 Form 15-12G under Exchange Act Rule 12g-4. Administrative only: it closes the SEC file and produces no tradable instrument and no cash to anyone.\n- **No listed acquirer print.** Chiesi is private, so EKTERLY performance will not surface through a quarterly US equity report.\n\n## Elapsed catalysts\n\n- **No issuer event is scheduled.** With reporting suspended since 2026-06-22 there is no earnings date, no guidance, no PDUFA and no shareholder meeting on the calendar for this issuer. The absence is itself the datapoint. *(passed 65d ago)*\n\n## What Would Change Our Mind\nThe dead label breaks only if the merger itself unwinds. Concretely: a court order or regulatory action rescinding a consummated second-step merger under Delaware law, followed by a fresh Nasdaq or NYSE listing application for KalVista common stock — a sequence with no working precedent in US deal history for a closed all-cash tender. A weaker version would be an OTC or expert-market quotation appearing under the symbol, or a market-maker Form 211 referencing KalVista common stock; that would create a quotable instrument without restoring the equity claim, and would be a data event rather than a thesis event. On price, the graded condition is that a daily close below $27.00 can no longer print — the series terminated at that level on 2026-06-10 and only a relisting reopens it. Also worth watching for the opposite failure: if the ~2026-09-20 Rule 12g-4 effectiveness comes and goes with no filing and no venue, that confirms the wind-down rather than changing anything.\n\n## Correlation Notes\n- **The comparable set lost a member.** Oral and next-generation HAE assets still listed include BioCryst (BCRX, oral prophylaxis ORLADEYO), Pharvaris (PHVS, oral on-demand deucrictibant), Astria (ATXS, navenibart) and Intellia (NTLA, NTLA-2002 gene editing). The **$27.00/share, ~$1.9B** print from 2026-06-11 is now a public take-out anchor those names get measured against; it is not a claim about their own economics.\n- **Factor exposure is undefined after 2026-06-10.** With no bars printing, KALV contributes no beta, no correlation and no drawdown to any basket — but an equal-weight screen or index still keying the symbol will carry a fixed $27.00 stub that quietly overstates momentum and understates volatility for the whole basket.\n- **Sector read-through is one-directional.** Chiesi's willingness to pay a 36% premium to the 30-day VWAP for a franchise at roughly $49M of 2025 revenue is a datapoint on strategic appetite for commercial-stage rare-disease assets; it says nothing about the tape KALV no longer prints on.",
  "first_seen": "2026-05-17",
  "last_analyzed": "2026-08-23T13:29:24+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}